Cargando…

Comparison of Three Different Chemotherapy Regimens Containing Epirubicin in Hormone-Refractory Prostate Cancer Patients

We compared three different chemotherapy regimens containing epirubicin in hormonerefractory prostate cancer (HRPC) patients. Sixty-nine patients with HRPC were randomized into three groups. The first group (22 patients) received 30 mg/m(2)/week i.v. epirubicin for 8 weeks. The second group (24 pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ersoy, Hamit, Yigitbası, Orhan, Sagnak, Levent, Topaloglu, Hikmet, Kiper, Ahmet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5848728/ https://www.ncbi.nlm.nih.gov/pubmed/18604442 http://dx.doi.org/10.1100/tsw.2008.90

Ejemplares similares

Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study
por: Ersoy, Hamit, et al.
Publicado: (2012)

The efficiency of a sedative or analgesic supplement to periprostatic nerve blockage for pain control during transrectal ultrasound-guided prostate biopsy – a prospective, randomized, controlled, double blind study
por: Ozok, Hakki U., et al.
Publicado: (2010)

A Comparison of Antegrade Percutaneous and Laparoscopic Approaches in the Treatment of Proximal Ureteral Stones
por: Topaloglu, Hikmet, et al.
Publicado: (2014)

Malfunctioned and Fractured Penile Prosthesis Caused by Cross Placement: Case Report
por: Karakoyunlu, Nihat, et al.
Publicado: (2015)

The preventive role of transurethral antibiotic delivery in a rat model
por: Ozok, Hakki U, et al.
Publicado: (2012)

Primary Signet Ring Cell Carcinoma of the Prostate: A Rare Case Report
por: Gök, Alper, et al.
Publicado: (2018)

Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer
por: Birtle, A J, et al.
Publicado: (2004)

Oncological and functional outcomes of open versus laparoscopic partial nephrectomy in T1b tumors: A single-center analysis
por: Kartal, Ibrahim, et al.
Publicado: (2020)

The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
por: Kiper, Ahmet, et al.
Publicado: (2005)

Weekly epirubicin in patients with hormone-resistant prostate cancer
por: Petrioli, R, et al.
Publicado: (2002)

The significance of Y chromosome microdeletion analysis in subfertile men with clinical variocele
por: Sagnak, Levent, et al.
Publicado: (2010)

Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
por: Yamasaki, Miho, et al.
Publicado: (2019)

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial
por: Pacilio, C, et al.
Publicado: (2006)

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.
por: Hernes, E. H., et al.
Publicado: (1997)

The Efficacy and Toxicity of Neoadjuvant Chemotherapy Regimens of Epirubicin Plus Cyclophosphamide Followed by Docetaxel or Paclitaxel in Female Breast Cancer Patients
por: Wu, Xian, et al.
Publicado: (2021)

Comparison of the effectiveness and toxicity of neoadjuvant chemotherapy regimens, capecitabine/epirubicin/cyclophosphamide vs 5-fluorouracil/epirubicin/cyclophosphamide, followed by adjuvant, capecitabine/docetaxel vs docetaxel, in patients with operable breast cancer
por: Zhang, Minmin, et al.
Publicado: (2016)

A New Method for Fragmented Ureteral Stent Extraction: Flexible Renoscopy
por: Hikmet, Topaloglu, et al.
Publicado: (2015)

Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX)
por: Wang, Yan, et al.
Publicado: (2016)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
por: Yao, Xin, et al.
Publicado: (2012)

A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy
por: Liu, Ching-Wen, et al.
Publicado: (2016)

The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer
por: Liu, Lei, et al.
Publicado: (2017)

Modified Epirubicin, cisplatin, and 5-FU regimen as first-line chemotherapy in metastatic gastric or gastroesophageal junction adenocarcinoma: A Phase II study
por: Babu, K. Govind, et al.
Publicado: (2019)

Pathogenesis of prostate cancer and hormone refractory prostate cancer
por: Girling, J. S., et al.
Publicado: (2007)

Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy
por: Cox, R A, et al.
Publicado: (2008)

Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience
por: Tralongo, Paolo, et al.
Publicado: (2016)

Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma
por: Tong, Xiwen, et al.
Publicado: (2023)

Changes in pubertal hormones, neurotransmitters and sleep patterns during sleep in girls with precocious puberty
por: Betul, Ersoy, et al.
Publicado: (2013)

Leptomeningeal Metastases in Hormone Refractory Prostate Cancer
por: Ng, Jessica Y, et al.
Publicado: (2018)

Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen
por: Kumar, Santosh, et al.
Publicado: (2010)

Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease
por: Asakura, Takanori, et al.
Publicado: (2019)

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)
por: Penault-Llorca, Frédérique, et al.
Publicado: (2018)

RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells
por: Liu, Tao, et al.
Publicado: (2018)

RNA interference-mediated depletion of TRPM8 enhances the efficacy of epirubicin chemotherapy in prostate cancer LNCaP and PC3 cells
por: Liu, Tao, et al.
Publicado: (2022)

Exquisite Sensitivity of TP53 Mutant and Basal Breast Cancers to a Dose-Dense Epirubicin−Cyclophosphamide Regimen
por: Bertheau, Philippe, et al.
Publicado: (2007)

Satraplatin in the treatment of hormone-refractory metastatic prostate cancer
por: Armstrong, Andrew J, et al.
Publicado: (2007)

Update in palliative management of hormone refractory cancer of prostate
por: Singh, Pratipal, et al.
Publicado: (2007)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity
por: Yang, Fang, et al.
Publicado: (2017)

Preventing effect of astragalus polysaccharide on cardiotoxicity induced by chemotherapy of epirubicin: A pilot study
por: Li, Xiaofang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_71e8h5q5f3h6hpee12au0ns5lp